ArticleThe journal of nutrition, health & aging2026
Possible sarcopenia defined by the 2025 Asian Working Group for sarcopenia consensus and functional impairment among adults aged 50-64 years: a longitudinal cohort study.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Asian Working Group for Sarcopenia (AWGS) 2025 consensus simplified possible sarcopenia assessment and extended it to adults aged 50-64 years, but its association with activities of daily living (ADL)/instrumental activities of daily living (IADL) impairment in this age group remains unclear. We therefore conducted cross-sectional and longitudinal analyses to address this gap.
methodsUsing China Health and Retirement Longitudinal Study data, we included 6,904 adults aged 50-64 years for cross-sectional analyses. After excluding participants with baseline impairment, 5,730 and 5,423 were followed through 2020 for incident ADL and IADL impairment, respectively. Transition analyses included 3,569 and 3,200 participants, respectively. Possible sarcopenia was defined as low handgrip strength according to the AWGS 2025 criterion. Multivariable logistic regression and discrete-time complementary log-log models were used.
resultsIn cross-sectional analyses, possible sarcopenia was associated with higher odds of prevalent ADL (OR = 1.82, 95% CI = 1.53-2.17) and IADL (OR = 1.45, 95% CI = 1.23-1.71) impairment. Over up to 9 years, it was associated with increased hazards of incident ADL (HR = 1.42, 95% CI = 1.27-1.59) and IADL (HR = 1.36, 95% CI = 1.21-1.52) impairment. In transition analyses, progression to possible sarcopenia was associated with higher hazards of subsequent ADL (HR = 1.23, 95% CI = 1.01-1.49) and IADL (HR = 1.31, 95% CI = 1.07-1.61) impairment. Reversion to no possible sarcopenia was not significantly associated with ADL (HR = 0.84, 95% CI = 0.58-1.22) or IADL (HR = 0.77, 95% CI = 0.52-1.15) impairment.
conclusionsAWGS 2025-defined possible sarcopenia and progression to possible sarcopenia were associated with ADL/IADL impairment in adults aged 50-64 years, supporting early screening and repeated monitoring in late midlife.
Indexed as
Identifiers
42880160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.